CANTICANTI home

Trials

Registry mirror rows for research browsing. Trial exists does not mean clinical benefit.

Open trial status does not mean eligibility or suitability. Review with oncology team.

Data: Live structured evidence (Supabase)

Open or active trials (128)

Open identifiers on the public registry for primary protocol text. Filter from unified search: NCT01631552

NCT IDTitleStatusPhaseConditionsInterventionsCountriesLast updatedSource
NCT03970447A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRECRUITINGPHASE2, PHASE3GlioblastomaTemozolomide, Lomustine, Regorafenib, Radiation +7Australia, Canada, France, Germany +22026-05-15CT.gov
NCT07590726PIRe 2.0: A Stepped-Care Model for Involving Relatives Across SectorsNOT_YET_RECRUITINGNABrain Injuries, Acute, Brain Tumor Adult, Brain (Nervous System) Cancers, Traumatic Brain Injuries +3Supportive CareDenmark2026-05-15CT.gov
NCT07485049BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted TumorsRECRUITINGEARLY_PHASE1Glioblastoma (GBM)BGB-58067United States2026-05-14CT.gov
NCT04003649IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBMACTIVE_NOT_RECRUITINGPHASE1Recurrent Glioblastoma, Refractory GlioblastomaIL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Ipilimumab, Nivolumab, Quality-of-Life Assessment +1United States2026-05-14CT.gov
NCT06973096CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial RadiotherapyRECRUITINGPHASE1GlioblastomaCART-EGFR-IL13Ra2 cells, Rituximab or Rituximab biosimilar, Fludarabine + Cyclophosphamide combinationUnited States2026-05-11CT.gov
NCT00268385Vorinostat and Temozolomide in Treating Patients With Malignant GliomasACTIVE_NOT_RECRUITINGPHASE1Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma +3Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, VorinostatUnited States2026-05-07CT.gov
NCT03115333DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent GlioblastomaACTIVE_NOT_RECRUITINGNAGliosarcoma, Recurrent GlioblastomaDynamic Susceptibility Contrast-Enhanced Magnetic Resonance ImagingUnited States2026-05-06CT.gov
NCT05708352A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care TreatmentRECRUITINGPHASE2Glioblastoma MultiformeKeto Diet, Standard Anti-Cancer DietUnited States2026-05-06CT.gov
NCT05241392Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent GlioblastomaACTIVE_NOT_RECRUITINGPHASE1GlioblastomaB7-H3-targeting CAR-T cellsChina2026-05-04CT.gov
NCT06556563EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaRECRUITINGPHASE3GlioblastomaOptune® device, Temozolomide, Pembrolizumab, PlaceboCanada, Czechia, France, Germany +82026-05-01CT.gov
NCT05765812A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaRECRUITINGPHASE1, PHASE2Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade IIIDebio 0123, Temozolomide, RadiotherapySpain, Switzerland, United States2026-04-28CT.gov
NCT06039709Sonodynamic Therapy in Patients With Recurrent GBMRECRUITINGPHASE1Recurrent Glioblastoma, Glioblastoma Multiforme, GBM5-ALA and Low-Intensity Focused Ultrasound (SDT)United States2026-04-28CT.gov
NCT07552233NK Cell Therapy for Malignant Solid Brain TumorsRECRUITINGNAMalignant Solid Brain Tumors, Glioblastoma (GBM), Glioblastoma Multiforme (GBM), Brain Metastasis +1Autologous NK cellsChina2026-04-27CT.gov
NCT07552467Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant TumorsRECRUITING-Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma +4Specific PET imaging agents targeting LRRC15China2026-04-27CT.gov
NCT07551336Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaRECRUITINGPHASE1Malignant Glioma, High-Grade Gliomas, Glioblastoma, Recurrent High-Grade Gliomas +1Dual-target CAR-NK cells, Cyclophosphamide, Intracranial catheter/reservoir for locoregional delivery, FludarabineChina2026-04-24CT.gov
NCT03383978Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive GlioblastomaRECRUITINGPHASE1GlioblastomaNK-92/5.28.z, EzabenlimabGermany2026-04-23CT.gov
NCT05843253Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantRECRUITINGPHASE2High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma +6Ribociclib, Everolimus, Temozolomide (TMZ)Australia, Canada, Germany, Netherlands +32026-04-22CT.gov
NCT06069726A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB TrialRECRUITINGPHASE2Recurrent GlioblastomaAtezolizumabUnited States2026-04-21CT.gov
NCT04656535AB154 Combined With AB122 for Recurrent GlioblastomaACTIVE_NOT_RECRUITINGEARLY_PHASE1GlioblastomaZimberelimab, Domvanalimab, PlaceboUnited States2026-04-17CT.gov
NCT02800486Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOARECRUITINGPHASE2Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma +5Intra-arterial Cetuximab, Intra-arterial Mannitol, Hypofractionated re-irradiationUnited States2026-04-13CT.gov
NCT07521657Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade GliomaNOT_YET_RECRUITINGPHASE2Neurofibromatosis 1 (NF1)mirdametinib with radiation, mirdametinibUnited States2026-04-13CT.gov
NCT07089641ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG TrialRECRUITINGPHASE1IDH Wildtype Glioblastoma, Recurrent Astrocytoma, IDH Wildtype Recurrent Glioblastoma, Resectable Astrocytoma +1Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18 +3United States2026-04-07CT.gov
NCT05474378B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma MultiformeRECRUITINGPHASE1Brain and Nervous SystemB7-H3CARTUnited States2026-04-07CT.gov
NCT06850766The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of GlioblastomaRECRUITINGNAIDH-Wildtype Glioblastoma, Glioblastoma (GBM)Morning administration of TMZ, Evening administration of TMZCanada2026-04-02CT.gov
NCT05839379Targeted Pediatric High-Grade Glioma TherapyRECRUITING-High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma +5-Australia, Canada, Germany, Netherlands +32026-03-31CT.gov
NCT03596086HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBMRECRUITINGPHASE1, PHASE2Glioblastoma Multiforme, Astrocytoma, Grade IIIADV/HSV-tk (gene therapy)United States2026-03-30CT.gov
NCT07413796Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted SuturesRECRUITINGNABrain Tumor Adult, Brain Tumor Benign, Meningioma, Glioma +1Absorbable running intradermal suture, Non-absorbable interrupted transdermal suturePoland2026-03-27CT.gov
NCT07493447Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical ProceduresNOT_YET_RECRUITINGEARLY_PHASE1Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer +1Panitumumab-IRDye800-2026-03-25CT.gov
NCT02586857A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)ACTIVE_NOT_RECRUITINGPHASE1, PHASE2Glioblastoma MultiformeACP-196United States2026-03-25CT.gov
NCT04678648A Trial of RSC-1255 for Treatment of Patients With Advanced MalignanciesRECRUITINGPHASE1Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer +2RSC-1255 Dose Escalation, RSC-1255 Dose ExpansionUnited States2026-03-18CT.gov
NCT06333899Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionRECRUITINGEARLY_PHASE1High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma +5Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post RadiationAustralia, Canada, Germany, Netherlands +22026-03-12CT.gov
NCT07457307Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-LinacNOT_YET_RECRUITINGPHASE1High-grade GliomaMR-Linac System, Radiation Therapy, TemozolomideUnited States2026-03-09CT.gov
NCT07268053A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain MetastasesRECRUITINGEARLY_PHASE1Glioblastoma (GBM), Brain MetastasasesRisvutatug rezetecanUnited States2026-03-06CT.gov
NCT04661384Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or MedulloblastomaACTIVE_NOT_RECRUITINGPHASE1Ependymoma, Glioblastoma, Medulloblastoma, Recurrent Metastatic Malignant Neoplasm in the LeptomeningesIL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-LymphocytesUnited States2026-03-05CT.gov
NCT03152318A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2ACTIVE_NOT_RECRUITINGPHASE1Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma +10rQNestin, Cyclophosphamide, Stereotactic biopsyUnited States2026-03-04CT.gov
NCT06672575A Phase I/II Study of IVONESCIMAB in Recurrent GlioblastomaRECRUITINGPHASE1, PHASE2GlioblastomaIvonescimabUnited States2026-02-27CT.gov
NCT07420543Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided ApproachRECRUITING-Brain Tumors and/or Solid Tumors Including, Glioblastoma, Glioblastoma (GBM), Glioblastoma - Category-Italy2026-02-19CT.gov
NCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsRECRUITING-Brain Tumor Adult, Brain Tumor Benign, CerebroSpinal Fluid (CSF) Leak, Craniotomy +3-Poland2026-02-17CT.gov
NCT07263438Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 TrialRECRUITINGPHASE2Glioblastoma, Recurrence TumorTrimipramine, Cohort 1: Atezolizumab, Bevacizumab, Cohort 2: Atezolizumab +1Switzerland2026-02-13CT.gov
NCT07387666Imaging Acetadote Metabolism in GlioblastomaNOT_YET_RECRUITINGEARLY_PHASE1Glioblastoma, GBMAcetadoteUnited States2026-02-06CT.gov
NCT03405792Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)ACTIVE_NOT_RECRUITINGPHASE2Glioblastoma, Glioblastoma, WHO Grade IVTemozolomide (TMZ), Optune System, PembrolizumabUnited States2026-02-06CT.gov
NCT07389278Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)NOT_YET_RECRUITINGPHASE1, PHASE2Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma, Diffuse Midline Glioma, H3 K27M-Mutant +1ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT)United States2026-02-05CT.gov
NCT05635734Azeliragon and Chemoradiotherapy in Newly Diagnosed GlioblastomaACTIVE_NOT_RECRUITINGPHASE1, PHASE2GlioblastomaAzeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mgSpain2026-02-05CT.gov
NCT05756985Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueRECRUITING-Glioblastoma, Glioblastoma Multiforme, GliosarcomaSpecimen CollectionUnited States2026-02-04CT.gov
NCT05653622Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated GlioblastomaRECRUITINGPHASE2Glioblastoma Multiforme, AdultIntegrated boost technique (SIB) guided by PET FDOPAFrance2026-02-04CT.gov
NCT03251027Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV GliomaACTIVE_NOT_RECRUITINGNAGlioblastoma, WHO Grade II Glioma, WHO Grade III GliomaIntensity-Modulated Radiation Therapy, Quality-of-LifeUnited States2026-01-27CT.gov
NCT07365280Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed GlioblastomaNOT_YET_RECRUITINGPHASE2GlioblastomaPersonalized Dendritic Cell Vaccine ZSNeo-DC1.1, Temozolomide (TMZ)-2026-01-26CT.gov
NCT04991870Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMRECRUITINGPHASE1Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial GliosarcomaCord Blood-derived Expanded Allogeneic Natural Killer Cells, ResectionUnited States2026-01-23CT.gov
NCT066302605G-RUBY: Avutometinib and Defactinib in Malignant Brain TumoursRECRUITINGPHASE1, PHASE2Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary GliomasAvutometinib, Defactinib, TemozolomideUnited Kingdom2026-01-21CT.gov
NCT04479696Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain TumorsRECRUITINGNAGlioblastoma, WHO Grade II Glioma, WHO Grade III GliomaEducational Intervention, Questionnaire Administration, Survey Administration, VideoUnited States2026-01-20CT.gov
NCT02179086Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaACTIVE_NOT_RECRUITINGPHASE2Glioblastoma3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis +5Canada, United States2026-01-14CT.gov
NCT05106296Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerRECRUITINGPHASE1Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain TumorIndoximod, Ibrutinib, Cyclophosphamide, Etoposide +2United States2026-01-09CT.gov
NCT04221503Niraparib/TTFields in GBMACTIVE_NOT_RECRUITINGPHASE2Glioblastoma, Recurrent Glioblastoma, GBMNiraparib, Optune, Planned surgical resectionUnited States2026-01-08CT.gov
NCT06558214OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd TrialRECRUITINGPHASE2Recurrent GlioblastomaPembrolizumab, Optune GIO®, NeuroBlate®United States2026-01-07CT.gov
NCT04959500Newly Diagnosed GlioblastomaACTIVE_NOT_RECRUITINGPHASE2GlioblastomaAnlotinib Hydrochloride, Placebo, Radiation Therapy, TemozolomideChina2026-01-02CT.gov
NCT07093814A Study of VRT106 for Injection in Patients With Recurrent/Progressive GlioblastomaRECRUITINGPHASE1, PHASE2GlioblastomaVRT106China2026-01-02CT.gov
NCT05879250WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaRECRUITINGPHASE2Glioblastoma, IDH-Wildtype, MGMT-Unmethylated GlioblastomaBiospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, STAT3 Inhibitor WP1066 +1United States2025-12-30CT.gov
NCT02177578Subventricular Zone (SVZ) and Temozolomide in Glioblastoma MultiformeACTIVE_NOT_RECRUITINGPHASE2Glioblastoma MultiformeTemozolomide, Subventricular Zone radiation, Neural Progenitor Cell Sparing radiationUnited States2025-12-18CT.gov
NCT05686798Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.RECRUITINGPHASE1Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor +5Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)United States2025-12-16CT.gov
NCT07284628Vortioxetine for Newly Diagnosed GlioblastomaNOT_YET_RECRUITINGPHASE2GlioblastomaVortioxetine-2025-12-16CT.gov
NCT02344355A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma MultiformeACTIVE_NOT_RECRUITINGPHASE2Glioblastoma MultiformeTemozolomide, radiation therapy, Ascorbic AcidUnited States2025-12-12CT.gov
NCT07274397Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for GlioblastomaNOT_YET_RECRUITINGNAGlioblastoma, Brain Tumors, Brain ImagingEarly post-operative brain PET-MRI with 18F-DOPA and Gadolinium-2025-12-10CT.gov
NCT05956821Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of AgeRECRUITINGPHASE1, PHASE2Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma +4SIACI of cetuximab and bevacizumabUnited States2025-12-08CT.gov
NCT06613841Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of GlioblastomaRECRUITINGEARLY_PHASE1Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme of BrainFluciclovine F18United States2025-11-28CT.gov
NCT04945148Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy TemozolomideRECRUITINGPHASE2Glioblastoma, IDH-wildtypeMetformin, Radiation IMRT, TemozolomideFrance, Italy2025-11-21CT.gov
NCT06072586A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or FusionsRECRUITINGEARLY_PHASE1High Grade Glioma, GlioblastomaBDTX-1535, BDTX-1535 combined with radiation therapy, BDTX-1535 combined with temozolomide and radiation therapyUnited States2025-11-20CT.gov
NCT07211841Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM)NOT_YET_RECRUITINGNAGlioblastoma, MRI Spectroscopy, Tumor Microenvironment, Biomarkers / BloodMRS study, blood samplesFrance2025-11-19CT.gov
NCT06831526Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed GlioblastomaRECRUITINGEARLY_PHASE1GlioblastomaAzeliragon, Temozolomide, Radiation therapy, Surgery or LITTUnited States2025-11-12CT.gov
NCT02977780INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)RECRUITINGPHASE2GlioblastomaTemozolomide, Neratinib, QBS10072S, Abemaciclib +1United States2025-11-10CT.gov
NCT02685605Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma MultiformeACTIVE_NOT_RECRUITINGPHASE3GlioblastomaStandard surgery, Intraoperative radiotherapy, Radiochemotherapy, TemozolomideBrazil, Canada, China, Germany +42025-10-14CT.gov
NCT07145112Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent GlioblastomaRECRUITINGPHASE1GlioblastomaLaser interstitial thermal therapy, LomustineUnited States2025-10-09CT.gov
NCT06059690Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma CellsRECRUITINGPHASE1, PHASE2Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor ReceptorpH Measurement of in vivo tissueUnited States2025-10-08CT.gov
NCT04214392Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive GlioblastomaACTIVE_NOT_RECRUITINGPHASE1Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III GliomaChlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery), Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)United States2025-10-06CT.gov
NCT06835803Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized TrialRECRUITINGPHASE2Glioblastoma (GBM)Dose-escalated radiation therapy, Standard hypofractionated radiationUnited States2025-09-18CT.gov
NCT06492486Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence WorkflowNOT_YET_RECRUITINGPHASE2Diffuse Glioma, Glioblastoma, Adaptive Radiotherapy, Artificial IntelligenceAdaptive radiotherapy-2025-09-16CT.gov
NCT07141732Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic BrachytherapyRECRUITINGPHASE1GlioblastomaResection of newly diagnosed glioblastoma combined with intraoperative balloon electronic brachytherapy using the Xoft® Axxent® Electronic Brachytherapy (eBx®) SystemRussia2025-09-16CT.gov
NCT05023551Study of DSP-0390 in Patients With Recurrent High-Grade GliomaACTIVE_NOT_RECRUITINGEARLY_PHASE1High Grade Glioma, Glioblastoma MultiformeDSP-0390Japan, United States2025-09-16CT.gov
NCT03958240Deciphering Mechanisms Underlying Cancer ImmunogenicityRECRUITINGNAHead and Neck Cancer, Ovarian Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia 3 +3Blood samples, tumor biopsy specimens and ascites samples will be collected.France2025-09-15CT.gov
NCT05120284Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)ACTIVE_NOT_RECRUITINGPHASE2Glioblastoma MultiformeDichloroacetate (DCA), GenotypeUnited States2025-08-29CT.gov
NCT04863950Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent GlioblastomaRECRUITINGPHASE2GlioblastomaLomustine, Imipramine HydrochlorideUnited States2025-08-27CT.gov
NCT04188535Serial MRI Scans During Radiation TherapyRECRUITINGNAGlioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging +4MRI IMAGINGUnited States2025-08-26CT.gov
NCT07138001Phase 2 Clinical Trial of KH617NOT_YET_RECRUITINGPHASE2Recurrent GlioblastomaKH617+TMZ, KH617, TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16-2025-08-22CT.gov
NCT06177964Lerapolturev (PVSRIPO) in GBMRECRUITINGPHASE2Recurrent Supratentorial GlioblastomaLerapolturev, Lomustine PillUnited States2025-08-17CT.gov
NCT02974621Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent GlioblastomaACTIVE_NOT_RECRUITINGPHASE2Recurrent GlioblastomaBevacizumab, Cediranib, Cediranib Maleate, OlaparibUnited States2025-08-03CT.gov
NCT05284643Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent GlioblastomaRECRUITINGNARecurrent GlioblastomaIntensity Modulated Proton Therapy (IMPT), BevacizumabUnited States2025-08-01CT.gov
NCT04135807Implantable Microdevice In Primary Brain TumorsRECRUITINGEARLY_PHASE1Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma +4MicrodeviceUnited States2025-07-23CT.gov
NCT05909618Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain MetastasesRECRUITINGPHASE2Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System, MGMT-Unmethylated GlioblastomaCrizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO], Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]Israel2025-07-22CT.gov
NCT07052877The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From BevacizumabNOT_YET_RECRUITING-Glioblastoma, Glioblastoma Multiforme (GBM)PSMA PET/CT scanAustralia2025-07-11CT.gov
NCT04780009Loupe-Based Intraoperative Fluorescence ImagingRECRUITING-Glioblastoma Multiforme, Anaplastic Astrocytoma-United States2025-07-09CT.gov
NCT06773481BC008-1A Injection for Recurrent CNS WHO G4 GliomaRECRUITINGPHASE1Glioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM) +1BC008-1A, BC008-1AChina2025-07-09CT.gov
NCT06954636Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudyRECRUITING-Glioblastoma Multiforme, Adult, Glioblastoma or Gliosarcoma, Glioblastoma, Adultolfactory testing (threshold and identification test)Germany2025-07-08CT.gov
NCT04047706Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaACTIVE_NOT_RECRUITINGPHASE1GlioblastomaIDO1 Inhibitor BMS-986205 25mg, Nivolumab, Radiation Therapy, Temozolomide +2United States2025-06-29CT.gov
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsRECRUITINGPHASE2Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer +14APL-101 Oral CapsulesAustralia, Canada, France, Hungary +72025-06-27CT.gov
NCT05879367Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or AstrocytomaRECRUITINGPHASE1Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype +3Eflornithine (Dose Level 1), Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), TemozolomideUnited States2025-06-25CT.gov
NCT06883747Clinical Trial of BMS-986504 in Recurrent GBM PatientsRECRUITINGEARLY_PHASE1Glioblastoma WHO Grade IVBMS-986504United States2025-06-19CT.gov
NCT03477513Personalized Radiation Therapy for GBMACTIVE_NOT_RECRUITINGNAGlioblastomaRadation TherapyUnited States2025-06-18CT.gov
NCT05775458Glutamate Excitotoxicity and Its Role in Glioblastoma BiologyRECRUITING-Brain Tumor, PrimaryBlood, CSF and tumor samplesItaly2025-06-11CT.gov
NCT06551909Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)RECRUITINGNAGlioblastomaNeoaddjuvant Stereotactic Radiotherapy with Simultaneous Integrated BoostItaly2025-06-08CT.gov
NCT06264388DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaRECRUITINGPHASE2High Grade Glioma, Anaplastic AstrocytomaDB107-RRV, DB107-FCUnited States2025-05-29CT.gov
NCT0649983118F-FET-PET/MRI vs Standard MRI Alone for Stereotactic RadioTherapy Planning for High Grade Brain GliomasACTIVE_NOT_RECRUITINGNAGlioma, Malignant0-(2-18F-Fluoroethyl)-L-TyrosineCanada2025-05-25CT.gov
NCT03897491PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type GlioblastomaACTIVE_NOT_RECRUITINGPHASE2Glioblastoma5-aminolevulinic acidGermany2025-05-14CT.gov
NCT06939400Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow FluorescenceNOT_YET_RECRUITING-Glioblastoma Multiforme (GBM)Photodynamic therapy (PDT), GBM patients recevied traditional treatment optionsChina2025-04-22CT.gov
NCT03688178DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without VarlilumabACTIVE_NOT_RECRUITINGPHASE2GlioblastomaHuman CMV pp65-LAMP mRNA-pulsed autologous DCs, Temozolomide, Varlilumab, Td +1United States2025-04-15CT.gov
NCT05460507Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL TreatmentRECRUITINGPHASE1GliomaRetreatment Rhenium LiposomeUnited States2025-03-30CT.gov
NCT03452579Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBMACTIVE_NOT_RECRUITINGPHASE2GlioblastomaNivolumab, Standard Dose Bevacizumab, Low Dose BevacizumabUnited States2025-02-28CT.gov
NCT04590664Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated GlioblastomaRECRUITINGPHASE1, PHASE2Glioblastoma, Recurrent GlioblastomaVerteporfinUnited States2025-02-25CT.gov
NCT06845020CSF Proteomic Characterization of GlioblastomasNOT_YET_RECRUITING-Glioblastoma, Glioblastoma WHO Grade IV, Glioblastoma (GBM), Glioblastoma Multiforme of the Brain +1--2025-02-25CT.gov
NCT05231655Ex VIvo DEtermiNed Cancer TherapyRECRUITING-Bladder Cancer, Kidney Cancer, Melanoma, Sarcoma +2Functional drug screenUnited Kingdom2025-02-24CT.gov
NCT06710249Impact of Salovum® and SPC® Flakes on Brain Tumor Induced EdemaRECRUITINGPHASE2Glioblastoma, Cerebral Metastases, MeningiomaSalovum/SPC flakesSweden2025-01-27CT.gov
NCT06097975A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent GlioblastomaRECRUITINGPHASE1Recurrent GlioblastomaNeo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV, Neurosurgery and intracavitary injection nivolumab and ipililumab, Adjuvant nivolumab IV + nivolumab and ipililumab intracavitaryBelgium2025-01-20CT.gov
NCT05590689Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain TumorRECRUITINGPHASE1, PHASE2GlioblastomaGliolan, Radiodynamic therapyGermany2024-12-16CT.gov
NCT06691308WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma PatientsNOT_YET_RECRUITINGEARLY_PHASE1Recurrent or Progressive GlioblastomaWL276 CAR-T cells-2024-11-18CT.gov
NCT01985087A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70ACTIVE_NOT_RECRUITINGPHASE1, PHASE2GlioblastomaHypofractionated radiotherapy, TemozolomideUnited States2024-10-31CT.gov
NCT06616727The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBMENROLLING_BY_INVITATIONPHASE1Recurrent Glioblastoma Multiforme (GBM)SNC109China2024-09-27CT.gov
NCT03630289Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBMACTIVE_NOT_RECRUITINGNAGlioblastoma, Glioblastoma Multiforme, GBM, Brain CancerTissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)United States2024-09-19CT.gov
NCT02649582Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma PatientsACTIVE_NOT_RECRUITINGPHASE1, PHASE2Glioblastoma Multiforme of BrainDendritic cell vaccine plus temozolomide chemotherapyBelgium2024-09-19CT.gov
NCT05271240Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBMRECRUITINGPHASE3Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM +3Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation, Temozolomide and Radiation AloneUnited States2024-09-19CT.gov
NCT06524063Targeted Survivin DC Cell Injection for the Treatment of GBMNOT_YET_RECRUITINGPHASE1GlioblastomaSurvivin-loaded dendritic cell injection-2024-07-29CT.gov
NCT05990556Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma PatientsRECRUITINGNAGlioblastoma, Meningeal Arteriesinterventional procedure to block bilateral meningeal blood supplyChina2024-07-24CT.gov
NCT06418113Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With GlioblastomaRECRUITINGPHASE1Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Radiotherapy; Complications +1hypofractionated stereotactic radiotherapy, Stereotactic biopsy, resection, Chemotherapy +2Spain2024-05-16CT.gov
NCT05768087Escalated Dose Proton Therapy Within the Multimodality Treatment of Glioblastoma PatientsRECRUITINGNAGlioblastomaEscalated proton therapyDenmark2024-05-09CT.gov
NCT06283927The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)RECRUITING-Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain +4Re-resection, Temozolomide, Lomustine, Re-irradiation +2Belgium, Germany, Netherlands, Switzerland +12024-02-28CT.gov
NCT06160596Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor PrognosisRECRUITING-Pancreas Adenocarcinoma, Small-cell Lung Cancer, Glioblastoma, IDH-wildtypeLong term survival multimodal analysisFrance2023-12-07CT.gov
NCT06146725The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)RECRUITING-Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult +1Tumor resection, Tumor biopsyBelgium, Germany, Netherlands, Switzerland +12023-11-27CT.gov
NCT06146738The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)RECRUITING-Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, AdultPalliative Care, Tumor biopsy, Tumor resectionBelgium, Germany, Netherlands, Switzerland +12023-11-27CT.gov
NCT05917821New Antigens Against GlioblastomaNOT_YET_RECRUITING-Glioblastoma Multiforme--2023-07-24CT.gov
NCT05541042Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic BiomarkersNOT_YET_RECRUITING-GlioblastomaObservational onlyChina2022-09-27CT.gov
NCT05502991Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse GlioblastomaNOT_YET_RECRUITINGPHASE2GlioblastomaTislelizumab plus BevacizumabChina2022-09-27CT.gov
Completed trials with indexed results (123)

Open identifiers on the public registry for primary protocol text. Filter from unified search: NCT01631552

NCT IDTitleStatusPhaseConditionsInterventionsCountriesLast updatedSource
NCT06796335Development and Implementation of an Intervention Enhancing Involvement of Relatives to Patients With Acquired Brain Injury or Malignant Brain TumourCOMPLETED-Brain Injury, Brain Tumor Adult, Traumatic Brain Injury, GlioblastomaRIGhtDenmark2026-05-07CT.gov
NCT06625047Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral ChemotherapyCOMPLETEDPHASE4Astrocytoma, IDH-Mutant, Glioblastoma, Glioma, Oligodendroglioma, IDH-Mutant and 1p/19q-CodeletedAssessment, Questionnaire Administration, Telemedicine Visit, TemozolomideUnited States2026-04-29CT.gov
NCT02631655POSitron Emission Imaging Using 18F-FDOPA in NeurooncologyCOMPLETEDNAGlioblastomaimpact of device 18F-FDOPA PET on treatment decisionsFrance2026-04-23CT.gov
NCT02286167Glioma Modified Atkins-based Diet in Patients With GlioblastomaCOMPLETEDNAGlioblastoma MultiformeDiet modificationUnited States2026-03-24CT.gov
NCT02669173Capecitabine + Bevacizumab in Patients With Recurrent GlioblastomaCOMPLETEDPHASE1GlioblastomaCapecitabine, BevacizumabUnited States2026-02-23CT.gov
NCT03048240INtraoperative photoDYnamic Therapy of GliOblastomaCOMPLETEDNAGlioblastoma"perPDT", GLIOLANFrance2026-02-05CT.gov
NCT01582269A Study in Recurrent Glioblastoma (GB)COMPLETEDPHASE2GlioblastomaGalunisertib, Lomustine, PlaceboAustralia, Belgium, Canada, France +62025-11-24CT.gov
NCT03975959Memory Perception Assessment in Central/Non-central Nervous System CancersCOMPLETEDNAGlioblastoma, Glioma, Breast Cancer, HealthyQMRP questionnaireFrance2025-09-23CT.gov
NCT03050736Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT ExpressionCOMPLETEDPHASE2Glioma, Glioblastoma, Glioblastoma Multiforme, GBM +1VAL-083 (Dianhydrogalactitol)China2025-09-04CT.gov
NCT03344250Phase I EGFR BATs in Newly Diagnosed GlioblastomaCOMPLETEDPHASE1Glioblastoma, Glioblastoma MultiformeEGFR BATs with TMZ following SOC RT/TMZ, Weekly EGFR BATs following SOC RT/TMZUnited States2025-03-06CT.gov
NCT03150862A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent GlioblastomaCOMPLETEDPHASE1, PHASE2Brain and Central Nervous System TumorsPamiparib, TMZ, RadiationAustralia, France, Netherlands, Switzerland +12025-02-04CT.gov
NCT02465268Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE2Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV +1pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline +1United States2025-01-14CT.gov
NCT01464177Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma MultiformeCOMPLETEDPHASE2Recurrent Glioblastoma MultiformeStereotactic hypofractionated RT 5x5Gy, Stereotactic hypofractionated RT 5x7GyBrazil2024-12-09CT.gov
NCT01837862A Phase I Study of Mebendazole for the Treatment of Pediatric GliomasCOMPLETEDPHASE1, PHASE2Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma +8Mebendazole, Vincristine, Carboplatin, Temozolomide +2United States2024-07-05CT.gov
NCT02490800Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade GliomaCOMPLETEDPHASE1, PHASE2NeoplasmsLisavanbulin Phase 1 dose escalation portion, Lisavanbulin Phase 2a expansion portionBelgium, Germany, Switzerland, United Kingdom2024-06-26CT.gov
NCT04143425Response Prediction for Anti-angiogenic Treatment in Recurrent GlioblastomaCOMPLETED-Adult Glioblastoma, Magnetic Resonance Imaging, Bevacizimab3-Tesla conventional magnetic resonance imaging, Advanced imaging without contrast use, Dynamic susceptibility contrast-weighted imagingSouth Korea2024-05-14CT.gov
NCT01922076Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine GliomasCOMPLETEDPHASE1Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant +2Adavosertib, Laboratory Biomarker Analysis, Pharmacological Study, Radiation TherapyCanada, United States2024-01-31CT.gov
NCT01421524Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple MyelomaCOMPLETEDPHASE1Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma +2CC-122, CC-122, CC-122, CC-122Belgium, France, Italy, Spain +12023-12-12CT.gov
NCT03463265Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed GlioblastomaCOMPLETEDPHASE2High Grade Recurrent Glioma and Newly Diagnosed Glioblastomanab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab, nab-sirolimus + lomustine +2United States2023-11-07CT.gov
NCT00751270Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant GliomasCOMPLETEDPHASE1Malignant Glioma, Glioblastoma Multiforme, Anaplastic AstrocytomaAdV-tk, ValacyclovirUnited States2023-08-25CT.gov
NCT02619864mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma MultiformeCOMPLETEDPHASE1Glioblastoma MultiformeAZD2014Canada2023-08-04CT.gov
NCT02661282Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With GlioblastomaCOMPLETEDPHASE1, PHASE2Cytomegalovirus Positive, Glioblastoma, Gliosarcoma, Malignant Glioma +2Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis, Temozolomide, Therapeutic Conventional SurgeryUnited States2023-06-18CT.gov
NCT02366728DC Migration Study for Newly-Diagnosed GBMCOMPLETEDPHASE2Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma MultiformeUnpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs, 111In-labeled DCs +3United States2023-06-08CT.gov
NCT01081223Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV GliomaCOMPLETEDPHASE1, PHASE2Glioma, High Grade Astrocytoma, Glioblastoma MultiformeCancer vaccine plus immune adjuvantUnited States2023-06-01CT.gov
NCT02573324A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) AmplificationCOMPLETEDPHASE3Glioblastoma, GliosarcomaTemozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414Argentina, Australia, Austria, Belgium +242023-05-11CT.gov
NCT02617589An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)COMPLETEDPHASE3Brain CancerNivolumab, Temozolomide, RadiotherapyAustralia, Austria, Belgium, Canada +152023-03-28CT.gov
NCT01607905Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor CancerCOMPLETEDPHASE1Solid TumorSelinexor, AcetaminophenCanada, Denmark, United States2023-01-26CT.gov
NCT02311920Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaCOMPLETEDPHASE1Gliosarcoma, Supratentorial GlioblastomaIpilimumab, Laboratory Biomarker Analysis, Nivolumab, TemozolomideUnited States2023-01-10CT.gov
NCT01865162Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot StudyCOMPLETEDPHASE1Glioblastoma Multiformeketogenic dietUnited States2022-11-09CT.gov
NCT03020017NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing SurgeryCOMPLETEDEARLY_PHASE1Gliosarcoma, Recurrent GlioblastomaLaboratory Biomarker Analysis, Pharmacological Study, Targeted Molecular TherapyUnited States2022-08-26CT.gov
NCT03367715Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated GlioblastomaCOMPLETEDPHASE2MGMT-unmethylated Glioblastoma (GBM), GBMNivolumab, Ipilimumab, Radiation Therapy (RT)United States2022-07-01CT.gov
NCT02968940Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant GlioblastomaCOMPLETEDPHASE2GlioblastomaAvelumab, Hypofractionated radiation therapy (HFRT)United States2022-06-29CT.gov
NCT01062399Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE1, PHASE2Brain and Central Nervous System Tumorsconcurrent RAD001 10 mg/day, concurrent temozolomide, Radiation therapy, concurrent RAD001 2.5 mg/day +3Canada, Israel, United States2022-06-09CT.gov
NCT02379572Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed GlioblastomasCOMPLETEDNAGlioblastomaiMRI-guided surgery, 5-ALA-guided surgeryGermany2021-10-22CT.gov
NCT01032200Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain TumorsCOMPLETEDPHASE2Brain Tumors, Nervous System Tumors, Cognition Disorders, FatigueArmodafinil, placeboUnited States2021-09-28CT.gov
NCT03034135Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent GlioblastomaCOMPLETEDPHASE2Recurrent GlioblastomaDisulfiram/Copper, Temozolomide (TMZ)United States2021-09-13CT.gov
NCT00070161Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain TumorCOMPLETEDPHASE2Brain and Central Nervous System Tumors, Radiation ToxicityEGb761, donepezil hydrochloride, cognitive assessmentUnited States2021-09-09CT.gov
NCT01851733MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma MultiformeCOMPLETEDPHASE1GlioblastomaMRI-guided Laser Heat Ablation (MLA), Doxorubicin, Blood draw - dendritic cells, Dynamic Susceptibility Contrast Magnetic Resonance ImagingUnited States2021-08-27CT.gov
NCT01631552Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerCOMPLETEDPHASE1, PHASE2Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer +12Sacituzumab Govitecan-hziy (SG)United States2021-08-12CT.gov
NCT01120639Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma MultiformCOMPLETEDPHASE1, PHASE2Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma MultiformeTemozolomide, Stereotactic Radiosurgery (SRS)United States2021-08-06CT.gov
NCT00293423GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive GliomaCOMPLETEDPHASE1, PHASE2Brain and Central Nervous System TumorsHSPPC-96, Standard Surgical ResectionUnited States2021-05-13CT.gov
NCT00590681Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE2Glioblastoma MultiformeBevacizumab and TemozolomideUnited States2021-03-30CT.gov
NCT02678975Disulfiram in Recurrent GlioblastomaCOMPLETEDPHASE2, PHASE3Glioma, GlioblastomaDisulfiram, Copper, Alkylating AgentsNorway, Sweden2021-03-18CT.gov
NCT00626483Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused LymphopeniaCOMPLETEDPHASE1Malignant Neoplasms BrainRNA-loaded dendritic cell vaccine, basiliximabUnited States2021-03-09CT.gov
NCT03603379Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade GliomasCOMPLETEDPHASE1GlioblastomaC225-ILs-doxSwitzerland2020-12-08CT.gov
NCT01013285Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCOMPLETEDPHASE2Brain and Central Nervous System Tumorsbevacizumab, temozolomide, external beam radiation therapyUnited States2020-09-21CT.gov
NCT00402116Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) PatientsCOMPLETEDPHASE1, PHASE2Glioblastoma, Glioblastoma Multiforme, Gliosarcomaenzastaurin, temozolomide, radiation therapyUnited States2020-08-06CT.gov
NCT00068510Vaccine Therapy in Treating Patients With Malignant GliomaCOMPLETEDPHASE1Brain and Central Nervous System Tumorstherapeutic autologous dendritic cellsUnited States2020-08-03CT.gov
NCT01790503A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed GlioblastomaCOMPLETEDPHASE1, PHASE2Patients With Newly Diagnosed GlioblastomaPLX3397, Radiation Therapy, TemozolomideUnited States2020-06-30CT.gov
NCT02502708Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain TumorsCOMPLETEDPHASE1Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor +4Indoximod, Temozolomide, Conformal Radiation, Cyclophosphamide +1United States2020-06-04CT.gov
NCT00795665Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade GliomaCOMPLETEDPHASE2Gliomabevacizumab, carmustineUnited States2020-05-12CT.gov
NCT02431572A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or ImmunotherapyCOMPLETEDNAIntracranial Tumors, Glioblastoma, MelanomaPBR PET, Cancer Immunotherapy, Radiation and chemotherapyUnited States2020-04-28CT.gov
NCT00036660SarCNU in Treating Patients With Recurrent Malignant GliomaCOMPLETEDPHASE2Brain and Central Nervous System TumorsSarCNUCanada2020-04-06CT.gov
NCT01989884An Efficacy Study Of Ortataxel In Recurrent GlioblastomaCOMPLETEDPHASE2GlioblastomaOrtataxelItaly2019-10-23CT.gov
NCT01514201Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine GliomasCOMPLETEDPHASE1, PHASE2Anaplastic Astrocytoma, Brain Stem Glioma, Childhood Mixed Glioma, Fibrillary Astrocytoma +93-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study +2United States2019-08-13CT.gov
NCT00884741Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed GlioblastomaCOMPLETEDPHASE3Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis +3Canada, Israel, United States2019-07-24CT.gov
NCT03626896Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) PatientsCOMPLETEDNAGlioblastoma Multiforme, Brain Tumor, Glioblastoma, Glioma +2NaviFUS SystemTaiwan2019-06-21CT.gov
NCT01478854Neural Progenitor Cell Sparing Radiation Therapy Plus TemozolomideCOMPLETEDNAGlioblastoma MultiformeRadiation, ChemotherapyUnited States2019-06-13CT.gov
NCT01109095CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBMCOMPLETEDPHASE1Glioblastoma Multiforme (GBM)HER.CAR CMV-specific CTLsUnited States2019-04-25CT.gov
NCT03660761Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant TumorsCOMPLETEDPHASE2Efficacy and Safetyapatinib, temodarChina2019-04-16CT.gov
NCT00093964Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)COMPLETEDPHASE2Glioblastoma MultiformeCilengitide 500 mg, Cilengitide 2000 mgUnited States2019-04-16CT.gov
NCT01846871Tivozanib for Recurrent GlioblastomaCOMPLETEDPHASE2GlioblastomaTivozanibUnited States2019-01-08CT.gov
NCT00720356Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCOMPLETEDPHASE2Brain and Central Nervous System Tumorsbevacizumab, erlotinib hydrochlorideUnited States2018-10-26CT.gov
NCT02253212Safety of BBB Opening With the SonoCloudCOMPLETEDPHASE1, PHASE2Glioblastoma, Glioma, Brain TumorSonoCloud, CarboplatinFrance2018-10-12CT.gov
NCT00433381Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or GliosarcomaCOMPLETEDPHASE2Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain NeoplasmBevacizumab, Irinotecan Hydrochloride, TemozolomideUnited States2018-09-17CT.gov
NCT02666066Radiomics for Prediction of Survival in GBMCOMPLETED-Glioblastoma, Glioma, Astrocytoma-Netherlands2018-08-17CT.gov
NCT02698280Bevacizumab and Nimustine in Patients With Recurrent High Grade GliomaCOMPLETEDPHASE2GlioblastomaBevacizumab, NimustineChina2018-07-31CT.gov
NCT01907165Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With TemozolomideCOMPLETEDEARLY_PHASE1GlioblastomaTemozolomide, Disulfiram, Copper gluconateUnited States2018-07-20CT.gov
NCT00006358Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain TumorCOMPLETEDPHASE2Brain and Central Nervous System Tumorstemozolomide, thalidomideUnited States2018-06-26CT.gov
NCT00022724CCI-779 in Treating Patients With Malignant GliomaCOMPLETEDPHASE1, PHASE2Brain and Central Nervous System TumorstemsirolimusUnited States2018-06-26CT.gov
NCT01985256Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain TumorCOMPLETEDPHASE1Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic OligoastrocytomaToca 511, Toca FCUnited States2018-05-21CT.gov
NCT00974987Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE2Brain and Central Nervous System TumorsBNCT(boron neutron capture therapy), XRT(X-ray radiation treatment), TMZ(temozolomide)Japan2018-04-25CT.gov
NCT00003474Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma MultiformeCOMPLETEDPHASE2Glioblastoma Multiforme of the BrainAntineoplaston therapy (Atengenal + Astugenal)United States2018-03-22CT.gov
NCT00782756Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant GliomaCOMPLETEDPHASE2Brain Cancer, Malignant Gliomaradiotherapy (RT) in combination with temozolomide and bevacizumabUnited States2018-02-06CT.gov
NCT01342757Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive GlioblastomaCOMPLETEDNAAdult Glioblastoma, Depression, Recurrent Adult Brain Tumorvorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administrationUnited States2018-01-29CT.gov
NCT00895180Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma MultiformeCOMPLETEDPHASE2Adult Glioblastoma Multiformeolaratumab, ramucirumabUnited States2017-12-27CT.gov
NCT01753713Dovitinib in Treating Patients With Recurrent or Progressive GlioblastomaCOMPLETEDPHASE2Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumordovitinib, laboratory biomarker analysisUnited States2017-12-12CT.gov
NCT01800695Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma MultiformeCOMPLETEDPHASE1Glioblastoma MultiformeABT-414, Temozolomide, Whole Brain Radiation-2017-11-21CT.gov
NCT01956734Virus DNX2401 and Temozolomide in Recurrent GlioblastomaCOMPLETEDPHASE1Glioblastoma Multiforme, Recurrent TumorDNX2401 and TemozolomideSpain2017-10-24CT.gov
NCT00045708A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade GliomasCOMPLETEDPHASE1, PHASE2Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumorixabepilone, pharmacological study, AnticonvulsantUnited States2017-10-18CT.gov
NCT00727506BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant GliomaCOMPLETEDPHASE2GliomaBIBW 2992, TMZ, BIBW 2992 plus TMZCanada, United States2017-08-15CT.gov
NCT00823797Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic GliomaCOMPLETEDPHASE2Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma +2Bendamustine Hydrochloride, Quality-of-Life AssessmentUnited States2017-07-07CT.gov
NCT00345163A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)COMPLETEDPHASE2Glioblastomabevacizumab, irinotecan-2017-05-16CT.gov
NCT00916409Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)COMPLETEDPHASE3Glioblastoma MultiformeNovoTTF-100A device, TemozolomideAustria, Canada, Czechia, France +82017-04-10CT.gov
NCT00643097Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE2Malignant Neoplasms of BrainPEP-3 vaccine, sargramostim, TemozolomideUnited States2017-02-01CT.gov
NCT00813943Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter StatusCOMPLETEDPHASE2GlioblastomaCilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide, RadiotherapyGermany, United States2017-01-30CT.gov
NCT00003996Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE2Brain and Central Nervous System Tumorscarmustine, chemotherapy, cisplatin, etoposide +1United States2016-12-07CT.gov
NCT02104882INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II StudyCOMPLETEDPHASE1, PHASE2Glioblastoma MultiformeIntraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)Germany2016-10-17CT.gov
NCT00302159Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain TumorsCOMPLETEDPHASE2High Grade Gliomas, Brain Tumorsadjuvant therapy, Temozolomide, Valproic Acid, Radiation therapyUnited States2016-08-18CT.gov
NCT01474239A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent GlioblastomaCOMPLETEDPHASE2Glioblastoma Multiformebevacizumab [Avastin], fotemustineItaly2016-03-15CT.gov
NCT00499473Sunitinib in Treating Patients With Recurrent Malignant GliomasCOMPLETEDPHASE2Adult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma +4sunitinib malate, pharmacological studyUnited States2016-02-29CT.gov
NCT00498927Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant GliomaCOMPLETEDPHASE2Brain and Central Nervous System Tumorstemozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis +1United States2016-02-29CT.gov
NCT00387933Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant GliomaCOMPLETEDPHASE1Brain and Central Nervous System Tumorshydroxyurea, imatinib mesylate, vatalanibUnited States2015-10-14CT.gov
NCT00704808Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)COMPLETED-GlioblastomaPrimary surgical treatment, Radiotherapy, Temozolomide-2015-09-09CT.gov
NCT00004146Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBMCOMPLETEDPHASE2Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcomaradiation therapy, carboxyamidotriazole, pharmacological studyUnited States2015-05-08CT.gov
NCT00821080Vandetanib and Sirolimus in Patients With Recurrent GlioblastomaCOMPLETEDPHASE1GlioblastomaSirolimus, VandetanibUnited States2015-05-01CT.gov
NCT00036894CC-5013 in Treating Patients With Recurrent GliomaCOMPLETEDPHASE1Brain and Central Nervous System TumorslenalidomideUnited States2015-04-30CT.gov
NCT00723827Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)COMPLETED-Glioblastoma, Glioma, AstrocytomaTemozolomide, Radiotherapy-2015-01-30CT.gov
NCT00689221Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter StatusCOMPLETEDPHASE3GlioblastomaCilengitide, Temozolomide, RadiotherapyGermany, United States2014-11-04CT.gov
NCT00576641Immunotherapy for Patients With Brain Stem Glioma and GlioblastomaCOMPLETEDPHASE1Brain Stem Glioma, Glioblastomaautologous dendritic cellsUnited States2014-10-30CT.gov
NCT00362921Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma MultiformeCOMPLETEDPHASE2Recurrent Adult Brain TumorGliadel wafers in combination with O6-benzylguanineUnited States2014-07-10CT.gov
NCT00095940Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System TumorsCOMPLETEDPHASE1, PHASE2Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma +4lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study +2United States2014-05-23CT.gov
NCT00238303Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCOMPLETEDPHASE2Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumorvorinostat, conventional surgeryUnited States2014-05-23CT.gov
NCT00611325Phase II Avastin + Bortezomib for Patients With Recurrent Malignant GliomaCOMPLETEDPHASE2Glioblastoma, GliosarcomaAvastin, BortezomibUnited States2014-03-12CT.gov
NCT00538850Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCOMPLETEDPHASE3CancerFentanyl sublingual spray, PlaceboUnited States2014-03-05CT.gov
NCT00875433Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid TumoursCOMPLETEDPHASE2NeoplasmsBIBW 2992United Kingdom2013-12-30CT.gov
NCT00575887Efficacy of Protracted Temozolomide in Patients With Progressive High Grade GliomaCOMPLETEDPHASE2Glioblastoma, Astrocytoma, Oligodendroglioma, Brain Tumor, RecurrentTemozolomideTurkey (Türkiye)2013-12-20CT.gov
NCT00003185Biological Therapy in Treating Patients With Glioblastoma MultiformeCOMPLETEDPHASE2Brain and Central Nervous System Tumorsautologous tumor cell vaccine, sargramostim, tumor-draining lymph node lymphocyte therapy, cyclophosphamide +1United States2013-12-04CT.gov
NCT00305656AZD2171 in Treating Patients With Recurrent Glioblastoma MultiformeCOMPLETEDPHASE2Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumorcediranib maleateUnited States2013-08-22CT.gov
NCT00039494Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain TumorsCOMPLETEDPHASE2Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcomaerlotinib hydrochloride, 3-dimensional conformal radiation therapy, temozolomideUnited States2013-08-02CT.gov
NCT00939991Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant GliomasCOMPLETEDPHASE1, PHASE2Brain Tumor, GlioblastomaVorinostst/Bevacizumab/TemozolomideUnited States2013-06-24CT.gov
NCT00004004Procarbazine in Treating Patients With Recurrent Brain TumorCOMPLETEDPHASE1, PHASE2Brain and Central Nervous System Tumorsprocarbazine hydrochlorideUnited States2013-06-21CT.gov
NCT00350727Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant GliomaCOMPLETEDPHASE2Gliomapazopanib, lapatinib-2013-04-19CT.gov
NCT00004024Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or OligodendrogliomaCOMPLETEDPHASE2Brain and Central Nervous System Tumorsaldesleukin, autologous tumor cell vaccine, muromonab-CD3, sargramostim +3United States2013-04-05CT.gov
NCT00301873Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant GliomaCOMPLETEDPHASE2Brain Tumors, Osteoporosis, Central Nervous System(CNS)MalignanciesIV ZometaUnited States2013-02-18CT.gov
NCT01089868Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme PatientsCOMPLETED-Glioblastoma Multiforme-Germany2012-08-07CT.gov
NCT00624728Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)COMPLETEDPHASE1, PHASE2High-grade Glioma, Astrocytoma, Glioblastoma18F Fluorothymidine PET CTFrance2012-05-04CT.gov
NCT00004073Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE2Brain and Central Nervous System Tumorssuramin, radiation therapyUnited States2012-05-03CT.gov
NCT00098761VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain TumorsCOMPLETEDPHASE1Brain and Central Nervous System TumorslaromustineUnited States2011-06-30CT.gov
NCT00006246Busulfan in Treating Children and Adolescents With Refractory CNS CancerCOMPLETEDPHASE1Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma +3busulfanUnited States2009-10-07CT.gov
NCT00003409Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE1Brain and Central Nervous System Tumorsmotexafin gadolinium, radiation therapyUnited States2009-02-09CT.gov
NCT00001148Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the TumorCOMPLETED-Astrocytoma, Glioblastoma, Glioma-United States2008-03-04CT.gov
NCT00430911Radiotherapy for Malignant Astrocytomas in the ElderlyCOMPLETEDPHASE3Primary Brain Tumor, Anaplastic Astrocytoma, Glioblastoma MultiformeRadiotherapyFrance2007-02-02CT.gov
Stopped or withdrawn trials (92)

These rows can provide caution or historical context. Filter from unified search: NCT01631552

NCT IDTitleStatusPhaseConditionsInterventionsCountriesLast updatedSource
NCT05557292RMC-5552 Monotherapy in Adult Subjects With Recurrent GlioblastomaTERMINATEDPHASE1Glioblastoma, Recurrent GlioblastomaRMC-5552United States2026-05-06CT.gov
NCT05753007A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma PatientsTERMINATEDPHASE2GlioblastomaCannabidiol (CBD), PlaceboUnited States2026-03-16CT.gov
NCT05267106Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 AlterationsTERMINATEDPHASE2Glioblastoma, Adult-type Diffuse GliomasPemigatinibDenmark, France, Germany, Italy +52025-12-30CT.gov
NCT05977322A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.TERMINATEDPHASE1Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Glioblastoma Multiforme68Ga-FF58, 177Lu-FF58Israel, Netherlands, Spain, Switzerland2025-12-24CT.gov
NCT06359379Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT PromoterTERMINATEDPHASE2Glioblastoma, IDH-wildtypeRopidoxuridineUnited States2025-12-18CT.gov
NCT05183204Paxalisib With a High Fat, Low Carb Diet and Metformin for GlioblastomaSUSPENDEDPHASE2GlioblastomaPaxalisib, Metformin, Ketogenic DietUnited States2025-12-18CT.gov
NCT06806228Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)SUSPENDEDPHASE1Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Gliosarcoma, Giant Cell Glioblastoma +1S-GboxinGeorgia, Kazakhstan, Ukraine2025-11-19CT.gov
NCT03107780Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain CancerTERMINATEDPHASE1Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma, Recurrent GlioblastomaBiospecimen Collection, Magnetic Resonance Imaging, Navtemadlin, Radiation TherapyUnited States2025-11-13CT.gov
NCT04657146Longitudinal Assessment of Marrow and Blood in Patients With GlioblastomaSUSPENDED-GlioblastomaBiorepositoryUnited States2025-11-12CT.gov
NCT04209790Neoadjuvant Chemoradiation for Resectable GlioblastomaTERMINATEDPHASE2Glioblastoma, Surgery, High Grade GliomaNeoadjuvant chemoradiation, Drug Therapy with Temozolomide (benzolamide) (Standard of Care), Surgery post Radiation and Temozolomide (benzolamide)United States2025-11-10CT.gov
NCT04424966Infigratinib in Recurrent High-Grade Glioma PatientsTERMINATEDEARLY_PHASE1Glioma, Glioblastoma, GBMInfigratinibUnited States2025-10-24CT.gov
NCT03868943Solriamfetol in Improving Sleep in Patients With Grade II-IV GliomaTERMINATEDPHASE2Glioma, GlioblastomaSoliramfetolUnited States2025-10-21CT.gov
NCT04963413RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.TERMINATEDPHASE1GlioblastomaAutologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSFUnited States2025-08-06CT.gov
NCT06501911A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade GliomaWITHDRAWNPHASE1Recurrent Glioblastoma, Recurrent High-grade GliomaBicalutamide, Intensity-modulated radiation therapy (IMRT)United States2025-07-22CT.gov
NCT04406272VB-111 in Surgically Accessible Recurrent/Progressive GBMTERMINATEDPHASE2Glioblastoma, Recurrent GlioblastomaVB11, Surgery, Placebo, BevacizumabUnited States2025-06-10CT.gov
NCT01430351Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation TherapyTERMINATEDPHASE1Glioblastoma, Gliosarcoma, Supratentorial GlioblastomaMefloquine, Memantine Hydrochloride, Metformin Hydrochloride, TemozolomideUnited States2025-05-07CT.gov
NCT04222309Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)SUSPENDEDPHASE1Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme +3Laparoscopically harvested omental free flapUnited States2025-04-09CT.gov
NCT05831995Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.TERMINATEDPHASE1Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 MutationABM-168United States2024-12-06CT.gov
NCT05973903Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of GlioblastomaWITHDRAWNPHASE1, PHASE2GBMLenvatinib, Pembrolizumab, Tumor Treating Fields (TTFields)-2024-12-04CT.gov
NCT05879120Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent GlioblastomaWITHDRAWNPHASE2Recurrent GlioblastomaPembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumabUnited States2024-11-20CT.gov
NCT03539731[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy VolunteersTERMINATEDPHASE1Healthy Subject, Intracranial Neoplasm, GlioblastomaFluorine F 18 DASA-23, Positron Emission TomographyUnited States2024-08-12CT.gov
NCT05370508A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBMTERMINATEDPHASE1, PHASE2Recurrent GBMSONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)United States2024-07-26CT.gov
NCT04047303CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and GlioblastomaTERMINATEDPHASE1Astrocytoma, GlioblastomaCC-90010Spain, United States2024-07-05CT.gov
NCT0422106118F-FluorThanatrace (PET/CT) in GlioblastomaTERMINATEDEARLY_PHASE1Glioblastoma18F-FluorThanatraceUnited States2024-06-17CT.gov
NCT04915404Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)TERMINATEDPHASE1, PHASE2Recurrent Glioblastoma MultiformeBerubicin HydrochloridePoland2024-06-06CT.gov
NCT04190628Safety and Tolerability of ABM-1310 in Patients With Advanced Solid TumorsTERMINATEDPHASE1Advanced Solid Tumor, BRAF V600 MutationABM-1310, CobimetinibUnited States2024-05-21CT.gov
NCT02546102Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in GlioblastomaSUSPENDEDPHASE3Glioblastoma MultiformeICT-107, PlaceboAustria, Canada, United States2024-04-03CT.gov
NCT03705351Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBMTERMINATEDPHASE1Glioblastoma, Cancer of Brain, Glioblastoma Multiforme, Brain TumorTumor Treating Fields, Temozolomide, Radiation TherapyUnited States2024-03-04CT.gov
NCT04218019Effect of Timing of Tumor-Treating Fields Plus Short-Course RadiationWITHDRAWNNANewly Diagnosed Glioblastoma in Patients ≥70 YearsTTFieldsGermany2024-01-05CT.gov
NCT04629209A Phase II, Open Label Study of ONC201 in Adults With EGFR-low GlioblastomaWITHDRAWNPHASE2GlioblastomaONC201United States2023-11-24CT.gov
NCT04541225Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsTERMINATEDPHASE1Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors +20NUV-422United States2023-07-14CT.gov
NCT00788125Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid TumorsTERMINATEDPHASE1, PHASE2Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer +7carboplatin, dasatinib, etoposide phosphate, ifosfamide +6United States2023-07-14CT.gov
NCT03332355Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2TERMINATEDPHASE1Glioblastoma Multiforme, Anaplastic AstrocytomaPAC-1 CompoundUnited States2023-05-24CT.gov
NCT01721577Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant AstrocytomasTERMINATEDPHASE1, PHASE2Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma +2AXL1717United States2023-05-22CT.gov
NCT03714334DNX-2440 Oncolytic Adenovirus for Recurrent GlioblastomaTERMINATEDPHASE1Glioblastoma, Glioblastoma, AdultDNX-2440 injectionSpain2023-04-07CT.gov
NCT01700569Phase-1 Study of Folinic Acid to Modulate MGMT Gene in GlioblastomaTERMINATEDPHASE1Grade IV Astrocytoma, GlioblastomaTemozolomide, folinic acid at pharmacological dose is the escalated drug, High voltage radiation therapy (linear accelerator)France2023-02-21CT.gov
NCT02664363EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant GliomaTERMINATEDPHASE1Glioblastoma, GliosarcomaEGFRvIII CAR T cellsUnited States2023-02-17CT.gov
NCT04200066A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent GlioblastomaWITHDRAWNPHASE1Glioblastoma, Brain TumorTemozolomide, Tamoxifen, Maprotiline-2022-08-22CT.gov
NCT03022578Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaTERMINATEDPHASE2IDH Family Wildtype, Recurrent Anaplastic Astrocytoma, Recurrent GlioblastomaLaser Interstitial Thermal Therapy, LomustineUnited States2022-08-10CT.gov
NCT02864368Peptide Targets for Glioblastoma Against Novel Cytomegalovirus AntigensTERMINATEDPHASE1Glioblastoma, Glioblastoma Multiforme5-day TMZ, 21-day TMZ, PEP-CMV: Component A, Tetanus-Diphtheria booster +2United States2022-06-09CT.gov
NCT04065087Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed GlioblastomaWITHDRAWNPHASE1, PHASE2Newly Diagnosed GlioblastomaGX-I7, PlaceboSouth Korea2022-03-17CT.gov
NCT01925573Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)TERMINATEDNARECURRENT GLIOBLASTOMA, Brain TumorOptune(NOVOTTF-100A)United States2022-02-03CT.gov
NCT03235934Glycemic Impact on Glioblastoma OutcomesWITHDRAWN-Glioblastoma Multiforme, Hyperglycemia-Canada2021-10-25CT.gov
NCT02283944TMS Electrochemotherapy for Glioblastoma MultiformeWITHDRAWNPHASE2GlioblastomaTMS-2021-09-20CT.gov
NCT02765165Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)TERMINATEDPHASE1, PHASE2Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2)USL311, USL311, USL311, LomustineSpain, United States2021-07-23CT.gov
NCT01433991A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)TERMINATEDPHASE1, PHASE2Advanced Solid TumorsGolvatinib, Lenvatinib, LenvatinibUnited States2021-06-08CT.gov
NCT02743078Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent GlioblastomaTERMINATEDPHASE2Glioblastoma, Glioma, GliosarcomaBevacizumab, TTFields TherapyUnited States2021-06-02CT.gov
NCT04854044ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent GlioblastomaWITHDRAWNPHASE1Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial GliosarcomaAkt/ERK Inhibitor ONC201, Radiation Therapy, ResectionUnited States2021-05-12CT.gov
NCT02433392Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme.TERMINATEDPHASE1GliomaCM-BC2United Kingdom2021-04-21CT.gov
NCT02255461Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsTERMINATEDPHASE1Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma +15palbociclib isethionate, pharmacological study, laboratory biomarker analysisUnited States2021-03-02CT.gov
NCT04270461NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid TumorsWITHDRAWNPHASE1Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon CancerNKG2D-based CAR T-cellsChina2020-10-22CT.gov
NCT02709889Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid TumorsTERMINATEDPHASE1, PHASE2Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma +4Rovalpituzumab tesirine, DexamethasoneUnited States2020-10-19CT.gov
NCT00323076[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine TumoursTERMINATEDPHASE1, PHASE2Renal Cell Carcinoma, Neuroendocrine Tumours18F-FAZA PET ImagingCanada2019-08-26CT.gov
NCT01966809Photodynamic Therapy (PDT) For Recurrent High Grade GliomasTERMINATEDPHASE2Brain Tumor, RecurrentPhotofrin photodynamic therapy.United States2019-08-20CT.gov
NCT00243022Dietary, Herbal and Alternative Medicine in Glioblastoma MultiformeTERMINATEDPHASE2Brain and Central Nervous System Tumors, Cerebral EdemaBoswellia serrata extract, cyanocobalaminUnited States2019-04-30CT.gov
NCT03403803Prognosis and Therapeutic Biomarkers for Glioblastoma PatientsTERMINATED-GlioblastomaOptuneUnited States2019-03-27CT.gov
NCT03176160LITT Palliative Treatment for Patients With Malignant GliomasWITHDRAWN-Malignant Glioma of Brain, GlioblastomaPalliative regimen consisting of LITTUnited States2019-02-27CT.gov
NCT03293888Spectral Analysis Probe to Identify Glioblastoma CellsTERMINATED-Glioblastoma-United States2019-01-25CT.gov
NCT00734526Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or GliosarcomaTERMINATEDPHASE1Glioblastoma, GliosarcomaTemozolomide, Radiation, SorafenibUnited States2018-11-09CT.gov
NCT02540135Fluorescein vs. iMRI in Resection of Malignant High Grade GliomaWITHDRAWNNAHigh Grade Malignant Neoplasm, Glioblastoma Multiforme, Anaplastic Astrocytomafluorescein, intraoperative MRIUnited States2018-07-20CT.gov
NCT03275558Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of GlioblastomaWITHDRAWNPHASE1Recurrent Glioblastoma, Gliosarcoma, Anaplastic GliomasAxitinib 1 MG, Sunitinib 5 MG, Pazopanib 5 MGHong Kong, Singapore2018-07-19CT.gov
NCT01870726Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent GlioblastomaTERMINATEDPHASE1, PHASE2c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBMINC280, BuparlisibGermany, Netherlands, Spain, Switzerland +12018-05-30CT.gov
NCT01702792Derivation of Tumor Specific HybridomasTERMINATEDPHASE1GlioblastomaTumor Vaccine-2018-04-04CT.gov
NCT01782976Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)WITHDRAWNPHASE2GlioblastomaCilengitide, Bevacizumab, Questionnaire-2018-01-19CT.gov
NCT01339039Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade GliomaTERMINATEDPHASE1High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma, Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO) +1Plerixafor, Plerixafor, Bevacizumab, Plerixafor +1United States2017-11-17CT.gov
NCT02039778Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade GliomaTERMINATEDNAGlioblastoma, Malignant Glioma, Brain Tumors, Anaplastic AstrocytomaStem Cell Radiotherapy (ScRT) and TemozolomideUnited States2017-06-05CT.gov
NCT02129335Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close PartnerTERMINATED-Neoplasms, GlioblastomastressSwitzerland2017-05-17CT.gov
NCT00436436O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation TherapyTERMINATEDPHASE2Brain and Central Nervous System TumorsO6-benzylguanine, temozolomideUnited States2017-03-28CT.gov
NCT02394665Dose Escalated MRSI Guided Radiation Therapy in GlioblastomaTERMINATEDPHASE2GlioblastomaIntensity Modulated Radiation Therapy, Temozolomide, Functional Assessment of Cancer Therapy-Brain (FACT-Br), Stereotactic Radiosurgery Boost +2United States2017-01-05CT.gov
NCT02841332Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent GlioblastomaTERMINATEDNAGlioblastomaF-MISO, Cerebral magnetic resonance imagery, Bevacizumab, Clinical examinationFrance2016-12-20CT.gov
NCT00473408The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade AstrocytomasTERMINATED-Anaplastic Astrocytoma, Glioblastoma Multiforme, Tumor AngiogenesisFunctional MRI (DCE-MRI), Blood sample, Tumor sampleNorway2016-12-06CT.gov
NCT01113463TPI 287 in Patients With Recurrent Glioblastoma MultiformeTERMINATEDPHASE2Brain CancerTPI 287United States2016-10-31CT.gov
NCT01445691More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided SurgeryWITHDRAWNPHASE2Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, Brain Neoplasms, Malignant +115-ALA (Gliolan)United States2016-05-17CT.gov
NCT01499251Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent GlioblastomaTERMINATEDPHASE1GlioblastomaPhase 1 Dose Escalation, Phase 1b, Ancillary StudyUnited States2016-05-05CT.gov
NCT01778530TRC105 for Recurrent GlioblastomaTERMINATEDPHASE2Glioblastoma MultiformeTRC105United States2015-10-07CT.gov
NCT01122888Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma MultiformeTERMINATEDPHASE1Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Solid Neoplasm +1Cilengitide, Clinical Observation, Laboratory Biomarker AnalysisUnited States2015-04-28CT.gov
NCT01378481High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent GliomaTERMINATEDPHASE1Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma +3Vorinostat, Stereotactic Radiosurgery, Laboratory Biomarker Analysis, Pharmacological Study +1United States2014-12-23CT.gov
NCT00761280Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary GlioblastomaTERMINATEDPHASE3Anaplastic Astrocytoma, Glioblastomatrabedersen, temozolomide, Drug delivery system for administration of AP 12009, Placement of Drug Delivery System +2Argentina, Austria, Brazil, Canada +122014-11-14CT.gov
NCT01854099Peptide Vaccine for Glioblastoma Against Cytomegalovirus AntigensWITHDRAWNPHASE1GlioblastomaPEP-CMV, PEP-CMV, PEP-CMV-2014-01-14CT.gov
NCT01011231Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent GliomaTERMINATEDPHASE2GlioblastomaGamma Knife RadiosurgeryUnited States2013-05-06CT.gov
NCT00005856Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma MultiformeTERMINATEDPHASE1, PHASE2Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcomaoxaliplatin, pharmacological studyUnited States2013-01-24CT.gov
NCT00797940Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)WITHDRAWNPHASE2Glioblastoma MultiformeIL-4PE-2012-12-03CT.gov
NCT00005790Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain TumorsWITHDRAWNNABrain and Central Nervous System Tumorslaboratory biomarker analysis, biopsy, magnetic resonance imaging, gadopentetate dimeglumine-2012-06-11CT.gov
NCT01044225Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated GlioblastomaTERMINATEDPHASE2GlioblastomaCetuximab, Cilengitide EMD 121974Belgium2012-03-22CT.gov
NCT01189513SCH-900105 in Recurrent GlioblastomaWITHDRAWNPHASE1GlioblastomaSCH 900105-2012-02-20CT.gov
NCT00508456Dietary Methionine Restriction Plus Temozolomide for Recurrent GBMTERMINATEDPHASE1Glioblastoma MultiformeTemodar (Temozolomide), Hominex-2United States2012-01-16CT.gov
NCT01105988Evaluating Tumor Pseudoprogression With FLT-PET and MRITERMINATEDEARLY_PHASE1GlioblastomaRadiologic examsUnited States2012-01-06CT.gov
NCT00290771Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)TERMINATEDPHASE2Recurrent Glioblastoma Multiforme (GBM)Imatinib tablets, Hydroxyurea capsulesUnited States2011-05-16CT.gov
NCT00003567Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaTERMINATEDPHASE1Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specificfilgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine +3United States2010-06-11CT.gov
NCT00376103Radiation Boost for Newly Diagnosed Glioblastoma MultiformeTERMINATEDPHASE1, PHASE2Glioblastoma Multiformetemozolomide, Brachytherapy, External Beam Radiation TherapyUnited States2009-09-18CT.gov
NCT00365222Phase II Study of Temozolomide in Newly Diagnosed GlioblastomaTERMINATEDPHASE2Glioblastoma, GliosarcomaTemozolomideUnited States2009-01-22CT.gov
NCT00083447Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma MultiformeWITHDRAWNPHASE3Glioblastoma MultiformeTransMID™Australia, United States2009-01-07CT.gov
Show other historical trials (113)
Other historical trials (113)

Open identifiers on the public registry for primary protocol text. Filter from unified search: NCT01631552

NCT IDTitleStatusPhaseConditionsInterventionsCountriesLast updatedSource
NCT04998864Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM PatientsCOMPLETED-Glioma, Malignant, GlioblastomaMagnetic Resonance guided Focused ultrasound (MRgFUS)Italy, Spain2026-04-16CT.gov
NCT04730869Metabolic Therapy Program In Conjunction With Standard Treatment For GlioblastomaCOMPLETEDNAGlioblastomaStandard Treatment Plus Metabolic Therapy ProgramNew Zealand2026-04-09CT.gov
NCT04801147Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE1, PHASE2GlioblastomaDendritic Cells VaccineItaly2026-03-27CT.gov
NCT04019002Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With GlioblastomaCOMPLETEDPHASE1Glioblastoma Multiforme (GBM)Hyperpolarized 13C PyruvateUnited States2026-03-27CT.gov
NCT06665724Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)COMPLETEDPHASE1Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Glioblastoma (GBM)5-Aminolevulinic acid Hydrochloride (Gliolan®), CV01Germany2026-02-27CT.gov
NCT04440358Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBMCOMPLETEDPHASE1, PHASE2Recurrent GlioblastomaExablate BBBD, CarboplatinCanada, Italy, South Korea2026-01-20CT.gov
NCT04474353Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed GlioblastomaCOMPLETEDPHASE1Glioblastoma, Newly Diagnosed GlioblastomaOptune, Gadolinium, Temozolomide, Stereotactic radiosurgery (SRS)United States2025-12-26CT.gov
NCT05190315Chlorpromazine and Standard of Care in GlioblastomaCOMPLETEDPHASE1Glioblastoma MultiformeChlorpromazine, Temozolomide, Radiation TherapyUnited States2025-09-02CT.gov
NCT01478178Safety Study of VAL-083 in Patients With Recurrent Malignant GliomaCOMPLETEDPHASE1, PHASE2Glioma, Glioblastoma, Glioblastoma Multiforme, GBM +1VAL-083 (Dianhydrogalactitol)United States2025-08-29CT.gov
NCT02717962Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent SettingCOMPLETEDPHASE2Glioma, Glioblastoma, Glioblastoma Multiforme, GBM +1VAL-083, DianhydrogalactitolUnited States2025-08-29CT.gov
NCT07120620PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed GlioblastomaCOMPLETEDPHASE1, PHASE2Glioblastoma Multiforme (GBM)TTFields before and during radiotherapy, TTFields before and during radiotherapyGermany2025-08-13CT.gov
NCT05362409Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade GliomaCOMPLETEDPHASE1High Grade Glioma5 Aminolevulinic Acid, CV01-delivered ultrasoundUnited States2025-06-19CT.gov
NCT04743310Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas SystemCOMPLETEDPHASE2Central Nervous System Tumortozuleristide, Canvas imaging system, Surgical resection of tumorUnited States2025-06-13CT.gov
NCT04051606Regorafenib in Bevacizumab Refractory Recurrent GlioblastomaCOMPLETEDPHASE2Recurrent GlioblastomaRegorafenibUnited States2025-06-05CT.gov
NCT05131815The BurnAlong Pilot Study for Adolescent and Young Adult Cancer SurvivorsCOMPLETEDNACancer, Cancer Metastatic, Neoplasms, Breast Cancer +18Virtual group based physical activity (BurnAlong) and Social Media Discussion BoardUnited States2025-02-26CT.gov
NCT01849146Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent GlioblastomaCOMPLETEDPHASE1Glioblastoma, Recurrent GlioblastomaAdavosertib, Radiation Therapy, TemozolomideUnited States2025-01-09CT.gov
NCT04280848Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in GlioblastomaCOMPLETEDPHASE2GlioblastomaUCPVax, TemozolomideFrance2025-01-09CT.gov
NCT04908176A Drug-drug Interaction Study of Avapritinib and MidazolamCOMPLETEDPHASE1Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) TumorsAvapritinib, midazolamUnited States2024-12-13CT.gov
NCT05015543Physical Training in Glioblastoma Patients During Cytotoxic TherapyCOMPLETEDNAGlioblastomaPersonal Training ProgramGermany2024-12-12CT.gov
NCT03865355Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma PatientsCOMPLETED-Glioma, Glioblastoma MultiformeNon- interventionalRussia2024-11-14CT.gov
NCT03922984Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in GlioblastomaCOMPLETEDNAGlioblastomaMRI with Arterial Spin Labeling (ASL)United States2024-10-22CT.gov
NCT06600399Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in GlioblastomaCOMPLETED-GlioblastomaglioblastomaChina2024-09-19CT.gov
NCT05977738Repurposed Drugs in Research for Cancer Clinical Trials- PitavastatinCOMPLETEDEARLY_PHASE1Glioblastoma Multiforme, Adult, Recurrent GlioblastomaPitavastatin calciumNetherlands2024-08-07CT.gov
NCT06038604Glioblastoma Psychosocial Support ProgramCOMPLETEDNAGlioblastomaPsychosocial Support InterventionUnited States2024-07-31CT.gov
NCT06346821Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World DataCOMPLETED-Glioblastoma MultiformeOptune® (Tumor Treating Fields)China2024-07-03CT.gov
NCT05402241IRD at Admission Predicts Survival of GBM Patients - a Prospective Pilot StudyCOMPLETED-Glioblastoma Multiforme-Canada2024-05-23CT.gov
NCT03454295Easing Psychosocial Burden for Informal CaregiversCOMPLETEDEARLY_PHASE1GlioblastomaFocus Group, Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C, Enhanced Usual Care / EUCUnited States2024-04-01CT.gov
NCT03466450Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed GlioblastomaCOMPLETEDPHASE1, PHASE2GlioblastomaPF-04449913, Temozolomide Oral CapsuleSpain2024-03-28CT.gov
NCT03770468Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in GlioblastomaCOMPLETED-GlioblastomaBlood drawlAustria, Belgium, France, Germany +52024-03-08CT.gov
NCT04552886Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult GlioblastomaCOMPLETEDPHASE1GlioblastomaTH-1 Dendritic Cell ImmunotherapyUnited States2024-01-11CT.gov
NCT02658981Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)COMPLETEDPHASE1Glioblastoma, Gliosarcoma, Recurrent Brain NeoplasmAnti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Pharmacological Study, Laboratory Biomarker Analysis +1United States2023-10-06CT.gov
NCT04119674Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed GlioblastomaCOMPLETEDPHASE1, PHASE2GlioblastomaDrug is Anlotinib., Drug is Temozolomide Capsule., Radiotherapy was initiated 4 to 6 weeks postoperatively.China2023-09-22CT.gov
NCT02330991A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First RelapseCOMPLETEDPHASE2GlioblastomaTemozolomide-2023-07-24CT.gov
NCT03726515CART-EGFRvIII + Pembrolizumab in GBMCOMPLETEDPHASE1GlioblastomaCART-EGFRvIII T cells, PembrolizumabUnited States2023-06-22CT.gov
NCT00584883A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE1Brain TumorABT 510United States2023-06-07CT.gov
NCT03618667GC1118 in Recurrent Glioblastoma Patients With High EGFR AmplificationCOMPLETEDPHASE2Glioblastoma, Adult, EGFR AmplificationGC1118South Korea2023-05-12CT.gov
NCT04091503Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With GlioblastomaCOMPLETEDPHASE1Glioma, Malignant, Gliosarcoma, Astrocytoma of BrainIntranasal Modified TemozolomideBosnia and Herzegovina, Bulgaria, Georgia2023-04-25CT.gov
NCT02444546Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain TumorsCOMPLETEDPHASE1Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma +6Laboratory Biomarker Analysis, Sargramostim, Wild-type ReovirusUnited States2023-04-24CT.gov
NCT04444427Evaluation of GLR2007 for Advanced Solid TumorsCOMPLETEDPHASE1, PHASE2Non-small Cell Lung Cancer, Glioblastoma MultiformeGLR2007United States2022-12-23CT.gov
NCT03291977Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)COMPLETEDPHASE3Glioblastoma, AdultFluorescéine Sodique Faure, White-light surgeryFrance2022-11-09CT.gov
NCT02885272FDG PET Imaging in Diagnosing Patients With GlioblastomaCOMPLETEDEARLY_PHASE1Brain GlioblastomaComputed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission TomographyUnited States2022-07-21CT.gov
NCT01808820Dendritic Cell (DC) Vaccine for Malignant Glioma and GlioblastomaCOMPLETEDPHASE1Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade GliomaDendritic Cell Vaccine, Tumor Lysate, Imiquimod, LeukapheresisUnited States2022-07-20CT.gov
NCT00752323Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant AstrocytomaCOMPLETEDPHASE2Brain and Central Nervous System Tumorsaminolevulinic acid, Surgical ResectionUnited States2021-09-17CT.gov
NCT03877861Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification AlgorithmsCOMPLETED-Glioma, GlioblastomaReadiband Sleep TrackingUnited States2021-06-09CT.gov
NCT04846257Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict RecurrenceCOMPLETED-GlioblastomaDynamic contrast-enhanced MRIEgypt2021-04-19CT.gov
NCT03033524Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent GlioblastomaCOMPLETEDPHASE2Recurrent GlioblastomaTTAC-0001-2021-01-27CT.gov
NCT01905228A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid NeoplasmCOMPLETEDPHASE1Solid Tumors, GlioblastomaCBL0137United States2020-12-10CT.gov
NCT00052208Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma MultiformeCOMPLETEDPHASE1, PHASE2Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcomagefitinib, radiation therapy, laboratory biomarker analysisUnited States2020-10-30CT.gov
NCT01048008Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced CancerCOMPLETEDPHASE1Advanced Cancer, Brain InvolvementDM-CHOC-PENUnited States2020-08-04CT.gov
NCT00509431Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant GliomaCOMPLETEDPHASE1Brain and Central Nervous System TumorsErlotinib + SirolimusUnited States2020-07-31CT.gov
NCT00255671Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain DisordersCOMPLETED-Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation ToxicityQuestionnaireUnited States2020-07-27CT.gov
NCT02223052Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCOMPLETEDPHASE1Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma +16CC-486, VidazaUnited States2020-05-12CT.gov
NCT02799238Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With GlioblastomaCOMPLETEDPHASE2GlioblastomaALECSAT, Radiotherapy, TemozolomideSweden2020-04-30CT.gov
NCT00009035Natural History of Patients With Brain and Spinal Cord TumorsCOMPLETED-Astrocytoma, Oligodendroglioma, Glioblastoma, Glioma +1-United States2019-12-12CT.gov
NCT02364206Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed GlioblastomaCOMPLETEDPHASE1, PHASE2Adult GlioblastomaLY2228820, Temozolomide, radiotherapyFrance2019-08-14CT.gov
NCT01009307Study of Blood and Cheek Cell Samples From Patients With GliomaCOMPLETED-Brain and Central Nervous System Tumorspolymorphism analysis, laboratory biomarker analysis, medical chart reviewUnited States2019-07-22CT.gov
NCT02575027Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma MultiformeCOMPLETEDNAGlioblastoma, Recurrent Brain NeoplasmPalliative Radiation Therapy, Questionnaire Administration, Radiation Therapy Treatment Planning and SimulationUnited States2019-02-28CT.gov
NCT01873469Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma MultiformeCOMPLETED-Glioblastoma MultiformeRadiochemotherapyGermany2019-02-18CT.gov
NCT00253669Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed GliomasCOMPLETED-Brain and Central Nervous System Tumors, Thromboembolismlaboratory biomarker analysis, physiologic testing, management of therapy complicationsUnited States2018-06-28CT.gov
NCT00006452Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma MultiformeCOMPLETEDPHASE1Brain and Central Nervous System Tumorsmotexafin gadolinium, radiation therapy-2018-06-27CT.gov
NCT02466828qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.COMPLETEDEARLY_PHASE1Glioblastoma, HypoxiaFeraheme®Canada2018-04-18CT.gov
NCT02507102A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in AustraliaCOMPLETEDNAGlioblastoma MultiformeVoyagerAustralia2018-03-30CT.gov
NCT01632228A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent GlioblastomaCOMPLETEDPHASE2GlioblastomaBevacizumab, Onartuzumab, PlaceboCanada, France, Germany, Italy +42018-02-05CT.gov
NCT00897663Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor TherapiesCOMPLETED-Brain and Central Nervous System Tumorsgene expression analysis, microarray analysis, protein expression analysis, diagnostic laboratory biomarker analysis +1United States2018-01-24CT.gov
NCT00730613Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant GliomaCOMPLETEDPHASE1Brain and Central Nervous System Tumorstherapeutic autologous lymphocytes, gene expression analysis, laboratory biomarker analysis-2017-10-09CT.gov
NCT00883298Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma MultiformeCOMPLETEDPHASE2Recurrent Glioblastoma Multiforme, Recurrent Gliosarcomatemozolomide and bevacizumabUnited States2017-03-30CT.gov
NCT01308684A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent GlioblastomaCOMPLETEDPHASE1Glioblastoma MultiformeRO5323441 + bevacizumab [Avastin], bevacizumab [Avastin]Denmark, France, Switzerland, United Kingdom2016-11-02CT.gov
NCT01588769A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme PatientsCOMPLETEDPHASE1Glioblastoma MultiformeALECSAT cell based immunotherapyDenmark2016-06-06CT.gov
NCT01833273Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVACOMPLETEDPHASE1Glioblastoma Multiform (Grade IV Astrocytoma)PolyMVAUnited States2016-06-03CT.gov
NCT00006342Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain TumorCOMPLETED-Brain and Central Nervous System Tumors, Lymphomachromosomal translocation analysis, gene rearrangement analysis, mutation analysisUnited States2015-10-15CT.gov
NCT01222221Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE1Brain and Central Nervous System Tumorsglioblastoma multiforme multipeptide vaccine IMA950, sargramostim, temozolomide, laboratory biomarker analysis +3United Kingdom2015-10-14CT.gov
NCT01102595Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable GlioblastomaCOMPLETEDPHASE2GlioblastomasTemozolomide, Bevacizumab, Standard radiation therapySpain2015-08-26CT.gov
NCT00003484Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain TumorsCOMPLETEDPHASE1Brain and Central Nervous System Tumors, Neuroblastomacarmustine, irinotecan hydrochloride, surgical procedure, iodine I 131 monoclonal antibody 81C6United States2015-04-23CT.gov
NCT00979862Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent GlioblastomaCOMPLETEDPHASE1Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain NeoplasmCediranib Maleate, Cilengitide, Laboratory Biomarker AnalysisUnited States2015-04-15CT.gov
NCT00049387Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCOMPLETEDPHASE1Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcomatipifarnib, temozolomide, radiation therapyUnited States2015-04-15CT.gov
NCT01582516Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent GlioblastomaCOMPLETEDPHASE1, PHASE2Brain Tumor, Recurring Glioblastomadelta-24-RGD adenovirusNetherlands2015-03-09CT.gov
NCT00024570Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant GliomaCOMPLETEDPHASE1, PHASE2Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed OligoastrocytomaIL13-PE38QQR, targeted fusion protein therapy, surgeryUnited States2014-11-14CT.gov
NCT00609999Ph I Dasatinib + Erlotinib in Recurrent MGCOMPLETEDPHASE1Glioblastoma, GliosarcomaErlotinib and DasatinibUnited States2014-07-16CT.gov
NCT00612989Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBMCOMPLETEDPHASE1Glioblastoma, GliosarcomaTemodar and O6-BenzylguanineUnited States2014-07-16CT.gov
NCT01699269Histopathologic Evaluation of High Grade Brain Tumors by High Order Diffusion Tensor ImagingCOMPLETEDNAHigh Grade Brain Tumorperitumoral glial cell infiltrationFrance2014-07-08CT.gov
NCT00677716Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First RelapseCOMPLETEDPHASE2Glioblastoma Multiforme131I-chTNT-1/B MAb (Cotara)India, United States2014-04-24CT.gov
NCT01273090Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or LymphomaCOMPLETEDPHASE1Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer +1imetelstat sodium, laboratory biomarker analysis, pharmacological studyCanada, United States2014-01-30CT.gov
NCT00979173Pharmacokinetics (PK) Study of AC480 for Recurrent GliomaCOMPLETEDPHASE1GliomaAC480United States2014-01-29CT.gov
NCT00253487Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed GliomasCOMPLETEDNABrain and Central Nervous System TumorsO6-benzylguanine, busulfan, temozolomide, adjuvant therapy +4-2014-01-06CT.gov
NCT00919737Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma MultiformeCOMPLETEDPHASE1, PHASE2Malignant GliomaNPC-08Japan2013-10-30CT.gov
NCT00070525Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem GliomaCOMPLETEDPHASE2Childhood High-grade Cerebral Astrocytoma, Childhood Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma +4tipifarnibUnited States2013-10-08CT.gov
NCT00039572Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the BrainCOMPLETEDPHASE1, PHASE2Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancerboronophenylalanine-fructose complexUnited States2013-06-26CT.gov
NCT00006268Immunotoxin Therapy in Treating Patients With Malignant GliomaCOMPLETEDPHASE1, PHASE2Brain and Central Nervous System Tumorscintredekin besudotox, isolated perfusion, conventional surgeryUnited States2013-06-24CT.gov
NCT00002572Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain TumorsCOMPLETEDPHASE1Brain and Central Nervous System Tumorsaldesleukin, muromonab-CD3, therapeutic tumor infiltrating lymphocytes, conventional surgeryUnited States2013-05-30CT.gov
NCT00780819Borderzone SamplingCOMPLETEDNAHigh Grade Glioma, GlioblastomaPoleStar N20 intraoperative MRINetherlands2013-05-14CT.gov
NCT00006368Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCOMPLETEDPHASE1Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor +4yttrium Y 90-edotreotideUnited States2013-05-01CT.gov
NCT00704080A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant GliomasCOMPLETEDPHASE1Mixed Gliomas, Malignant Gliomas, Glioblastoma MultiformeXL765 (SAR245409), TemozolomideUnited States2013-04-10CT.gov
NCT00316849Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE1Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcomapharmacological study, adjuvant therapy, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy +2United States2013-04-10CT.gov
NCT00045565Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCOMPLETEDPHASE1Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcomaarsenic trioxide, radiation therapyUnited States2013-04-09CT.gov
NCT01100177Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma PatientsCOMPLETEDPHASE2GlioblastomaSunitinib, RadiationSpain2013-03-11CT.gov
NCT00003348Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the BrainCOMPLETEDPHASE1Brain and Central Nervous System TumorsO6-benzylguanine, carmustineUnited States2013-02-20CT.gov
NCT00613223Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant GliomasCOMPLETEDPHASE1Gliosarcoma, GlioblastomaVandetanib and EtoposideUnited States2013-02-20CT.gov
NCT00053963FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCOMPLETEDPHASE1Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia +21romidepsinUnited States2013-01-16CT.gov
NCT00357253Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade GliomaCOMPLETEDPHASE1Brain and Central Nervous System Tumorscapecitabine, radiation therapyUnited States2013-01-10CT.gov
NCT00190424Randomized Phase 2 With CpG-ODN in Malignant GlioblastomaCOMPLETEDPHASE2GlioblastomaCpG-ODNFrance2012-12-13CT.gov
NCT00753246Nimotuzumab in Adults With Glioblastoma MultiformaCOMPLETEDPHASE3Adults With Glioblastoma MultiformanimotuzumabGermany2012-12-03CT.gov
NCT00409214Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of GliomaCOMPLETEDPHASE2Glioma, Glioblastoma Multiforme, Anaplastic AstrocytomaLS11 (talaporfin sodium), Light source (interstitial light emitting diodes), Intraoperative placement of device in gliomaSerbia2012-11-16CT.gov
NCT00002619Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem TumorsCOMPLETEDPHASE2Brain and Central Nervous System Tumorsfilgrastim, carboplatin, thiotepa, autologous bone marrow transplantation +1United States2012-11-09CT.gov
NCT00071539Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain TumorsCOMPLETEDPHASE2Recurrent Glioblastoma MultiformeTP-38, TP38-2012-01-20CT.gov
NCT00209989Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma MultiformeCOMPLETEDPHASE2Glioblastoma MultiformeZarnestra, standard Radiation therapyFrance2011-11-24CT.gov
NCT00104091Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain TumorsCOMPLETEDPHASE2Glioblastoma MultiformeTP-38-2011-05-23CT.gov
NCT00010036Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma MultiformeCOMPLETEDPHASE2Brain and Central Nervous System Tumorscarboplatin, irinotecan hydrochloride, radiation therapyUnited States2011-03-28CT.gov
NCT00025558Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain CancerCOMPLETEDPHASE1Brain and Central Nervous System Tumorsfilgrastim, carboplatin, temozolomide, thiotepa +2Australia, United States2011-03-28CT.gov
NCT00800917A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma MultiformeCOMPLETEDPHASE2Glioblastoma MultiformeTemsirolimus, BevacizumabDenmark2010-06-02CT.gov
NCT00053183Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCOMPLETEDPHASE1Brain and Central Nervous System Tumorsconventional surgery, brachytherapy, radiation therapyUnited States2009-02-09CT.gov
NCT00032097Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the BrainCOMPLETEDPHASE1Brain and Central Nervous System Tumorsmotexafin gadolinium, radiation therapyUnited States2009-02-09CT.gov
NCT00075894Alanosine in Treating Patients With Progressive or Recurrent Malignant GliomasCOMPLETEDPHASE1Brain and Central Nervous System TumorsL-alanosineUnited States2009-01-13CT.gov
NCT00463073Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant GlioblastomasCOMPLETEDPHASE2Malignant GliomasCetuximab, Bevacizumab, IrinotecanDenmark2008-12-11CT.gov
Show other historical trials (44)
Other historical trials (44)

Open identifiers on the public registry for primary protocol text. Filter from unified search: NCT01631552

NCT IDTitleStatusPhaseConditionsInterventionsCountriesLast updatedSource
NCT05551013Treatment of Recurrent GBM With APG-157 Via Expanded AccessNO_LONGER_AVAILABLE-Glioblastoma, Glioblastoma MultiformeAPG-157-2024-08-09CT.gov
NCT04600817A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)UNKNOWNPHASE2Newly Diagnosed GlioblastomaTJ107, TJ107 placeboChina, Hong Kong2024-04-15CT.gov
NCT04573192A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First ProgressionUNKNOWNPHASE1, PHASE2GlioblastomaL19TNF, LomustineFrance, Germany, Italy, Switzerland2024-04-08CT.gov
NCT06186440Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated GlioblastomaUNKNOWNPHASE1, PHASE2Glioblastoma Multiforme of BrainCisplatin Plus Temozolomide, Temozolomide-2024-01-02CT.gov
NCT04671459TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-ThyrosineUNKNOWNPHASE2Glioblastoma Multiforme, Recurrent GlioblastomaTTFields and SRSPoland2023-06-28CT.gov
NCT05191784GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) PatientsUNKNOWNPHASE2Recurrent GlioblastomaGX-I7, BevacizumabSouth Korea2023-06-12CT.gov
NCT05694416Etoposide Plus Cisplatin Compared With Temozolomide in Patients With GlioblastomaUNKNOWNPHASE2MGMT-Unmethylated GlioblastomaEtoposide Plus Cisplatin-2023-01-23CT.gov
NCT05512195Safety and Efficacy of a New Approach to Delineating Clinical Target Volume of GlioblastomaUNKNOWNNAGlioblastomaNew delineation approach-2022-08-23CT.gov
NCT05399524Functional and Ultrasound Guided Resection of GlioblastomaUNKNOWNNAGlioma Glioblastoma MultiformeStandard of Care, Additional pre- and intra-operative imagingUnited Kingdom2022-06-01CT.gov
NCT00045968Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain CancerUNKNOWNPHASE3Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma +3Dendritic cell immunotherapyCanada, Germany, United Kingdom, United States2022-05-18CT.gov
NCT05333588The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.UNKNOWNEARLY_PHASE1Glioblastoma Multiforme, AdultTumor Infiltrating Lymphocytes (TIL)China2022-04-19CT.gov
NCT05131763NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid TumorsUNKNOWNPHASE1Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon CancerNKG2D-based CAR T-cellsChina2021-11-23CT.gov
NCT05053880A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma MultiformeUNKNOWNPHASE1, PHASE2Recurrent Glioblastoma Multiforme(GBM)ACT001, ACT001 + PembrolizumabUnited States2021-11-19CT.gov
NCT04970615Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed ModelsUNKNOWN-Brain Tumor, Glioma, Glioblastoma, Astrocytoma +4Three-dimensional printed modelNetherlands2021-07-21CT.gov
NCT04902586Effect of Radiotherapy Concurrent of TTFields in Patients With GlioblastomaUNKNOWNNAGlioma, GlioblastomaTTFieldsChina2021-05-26CT.gov
NCT04180046Utility of Primary Glioblastoma Cell LinesUNKNOWN-Tumor, Brain Tumor-Italy2021-04-12CT.gov
NCT04772846Chloroquine for Glioblastoma.UNKNOWNPHASE1, PHASE2GlioblastomaOral tablet, PlaceboEgypt2021-02-26CT.gov
NCT04547621HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBMUNKNOWNPHASE1, PHASE2Glioma, MalignantRadiation, Radiation, TemozolomideChina2020-09-14CT.gov
NCT04547855Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP RegimenUNKNOWNPHASE2Glioblastomaanlotinib combined with dose-dense temozolomideChina2020-09-14CT.gov
NCT04536649Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma.UNKNOWNPHASE3GlioblastomaRadiotherapyChina2020-09-02CT.gov
NCT03914768Immune Modulatory DC Vaccine Against Brain TumorUNKNOWNPHASE1Diffuse Intrinsic Pontine Glioma or GlioblastomaImmunomodulatory DC vaccine to target DIPG and GBMChina2020-06-12CT.gov
NCT00276783Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain MetastasesUNKNOWNPHASE2Brain and Central Nervous System Tumors, Lymphoma, Metastatic CancerpemetrexedUnited States2020-03-05CT.gov
NCT03567135Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for GlioblastomaUNKNOWN-GlioblastomaApatinib, Temozolomide（TMZ）China2020-03-03CT.gov
NCT00275067Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By SurgeryUNKNOWNPHASE1, PHASE2Brain and Central Nervous System Tumorsarsenic trioxide, temozolomide, radiation therapyUnited States2020-02-25CT.gov
NCT03409549Multi-parametric MRI/Fluorine-18 Fluciclovine PET-CT in GlioblastomaUNKNOWN-Tumor, BrainFluciclovine PET/CTUnited Kingdom2019-08-06CT.gov
NCT02520635Supra-early Post-Surgery Chemotherapy in the Treatment on GBM PatientsUNKNOWN-Glioblastomasupra-early TEMODAL® chemotherapy, standard TEMODAL® chemotherapy, Radiotherapy 60GyChina2019-07-11CT.gov
NCT03687034A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With GlioblastomaUNKNOWNPHASE1GlioblastomaTemozolomide, Optune-2019-02-26CT.gov
NCT03642080MRI Predictors of Response to Tumor Treating FieldsUNKNOWN-Glioblastoma Multiforme-United States2018-12-19CT.gov
NCT03633552Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade GliomaUNKNOWNPHASE3Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of BrainTemozolomideIran2018-08-16CT.gov
NCT02945826uPAR-PET/MRI in Glioblastoma MultiformeUNKNOWNPHASE2Glioblastoma MultiformeOne injection of 68Ga-NOTA-AE105, PET/MRIDenmark2018-04-10CT.gov
NCT03370926FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing RadiotherapyUNKNOWN-Glioblastoma Multiforme, Anaplastic Astrocytoma, Radiotherapy-France2017-12-13CT.gov
NCT02152748Disease Progression and Treatment-induced Alterations in GlioblastomaUNKNOWN-Brain Tumoranalyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistanceAustria2017-03-22CT.gov
NCT02815410Validation of the Role of Levetiracetam for Newly Diagnosed GBM PatientsUNKNOWNPHASE2Glioblastoma Multiformelevetiracetam-2016-06-28CT.gov
NCT01939574A Explore Study of Bevacizumab Combined With Conventional Therapy in GlioblastomaUNKNOWNNAGlioblastomaChemoradiation Therapy, Adjuvant TherapyChina2016-01-21CT.gov
NCT02623231The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma PatientsUNKNOWNPHASE2, PHASE3GBM, DepressionEscitalopram, placeboIsrael2015-12-07CT.gov
NCT00516607Enzastaurin and Temozolomide in Treating Patients With Primary GliomasUNKNOWNPHASE1Brain and Central Nervous System Tumorsenzastaurin hydrochloride, temozolomide, pharmacological studyUnited Kingdom2015-02-10CT.gov
NCT01637753Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant GliomaUNKNOWNNAAnaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, GlioblastomaCarmustine(BCNU), SurgeryChina2012-07-11CT.gov
NCT01124240Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter GeneUNKNOWNPHASE2Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4CilengitideAustralia2011-07-26CT.gov
NCT01317888Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade GliomasUNKNOWNNAGlioblastoma Multiforme, Astrocytoma Anaplastic FociMAB-425 radiolabeled with I-125-2011-03-17CT.gov
NCT00562419CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With IrinotecanUNKNOWNPHASE2Brain and Central Nervous System Tumors, Recurrent Glioblastoma MultiformeCT-322, irinotecan hydrochlorideUnited States2010-10-27CT.gov
NCT01208909Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)UNKNOWN-Glioblastomadiagnostic 5-ALA and MRI for tumor resectionSwitzerland2010-10-22CT.gov
NCT00906516Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma MultiformeUNKNOWNPHASE2Brain TumorsNeuradiab in combination with Bevacizumab (Avastin)United States2009-05-21CT.gov
NCT00114309131-I-TM-601 Study in Adults With Recurrent High-Grade GliomaUNKNOWNPHASE2Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma +2131-I-TM-601, 131I-TM601United States2009-04-03CT.gov
NCT00394628AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma MultiformeUNKNOWNPHASE1, PHASE2Glioblastoma MultiformeAQ4N, Temozolomide, RadiotherapyUnited States2007-05-30CT.gov